-

10:12:14 PM

LHDX Stock News

LHDX - Lucira Health Inc

11/22/22 4:02 PM

Nasdaq : LHDX

covid-19

Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit

RHEA-AI

neutral

11/17/22 7:03 AM

Nasdaq : LHDX

Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and

RHEA-AI

neutral

11/14/22 4:02 PM

Nasdaq : LHDX

Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

RHEA-AI

neutral

11/01/22 7:00 AM

Nasdaq : LHDX

earnings

Lucira Health to Announce Third Quarter 2022 Financial Results

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect

RHEA-AI

neutral

09/29/22 7:00 AM

Nasdaq : LHDX

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health” or “Lucira”), a medical technology company, today announced interim results

RHEA-AI

positive

09/07/22 7:00 AM

Nasdaq : LHDX

conferences

Lucira Health to Participate in LifeSci Partners HealthTech Symposium

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, and a digital health platform that will connect

RHEA-AI

neutral

08/23/22 7:00 AM

Nasdaq : LHDX

conferences

Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate

RHEA-AI

neutral

08/15/22 4:01 PM

Nasdaq : LHDX

Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

RHEA-AI

positive

08/11/22 7:01 AM

Nasdaq : LHDX

covid-19

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that

RHEA-AI

neutral

08/02/22 7:00 AM

Nasdaq : LHDX

earnings

Lucira Health to Announce Second Quarter 2022 Financial Results

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second

RHEA-AI

neutral

1 2 3 4 5 6 Next

LHDX Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.lucirahealth.com
Security nameLucira Health Inc
Issue typecs
SectorManufacturing
Sic code2835
Employees57

About Lucira Health Inc

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.